Bleichroeder group discloses 4.61% CLRB stake in amended ownership filing

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. received an updated ownership report from Bleichroeder-related entities on a Schedule 13G/A. Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 200,000 common shares, representing 4.61% of the company’s common stock.

The filing notes that Bleichroeder LP, a registered investment adviser, is deemed the beneficial owner because it manages these holdings for various clients. Those clients have the right to receive dividends and sale proceeds. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Cellectar Biosciences.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cellectar Biosciences, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

15117F880

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15117F880

1

Names of Reporting Persons

Bleichroeder LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 200,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 200,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.61 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 15117F880

1

Names of Reporting Persons

Bleichroeder Holdings LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 200,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 200,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.61 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 15117F880

1

Names of Reporting Persons

Andrew Gundlach

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 200,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 200,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.61 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cellectar Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 100 CAMPUS DRIVE, FLORHAM PARK, NJ 07932
Item 2.
(a)	Name of person filing: Bleichroeder Holdings LLC Bleichroeder LP Andrew Gundlach
(b)	Address or principal business office or, if none, residence: 1345 Avenue of the Americas, 47th Floor New York, NY 10105
(c)	Citizenship: Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA Andrew Gundlach: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 15117F880
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See cover page.
(b)	Percent of class: See cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See cover page.
	(ii) Shared power to vote or to direct the vote: See cover page.
	(iii) Sole power to dispose or to direct the disposition of: See cover page.
	(iv) Shared power to dispose or to direct the disposition of: See cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 200,000 shares, or 4.61% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.1
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	02/13/2026

Bleichroeder Holdings LLC

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	02/13/2026

Andrew Gundlach

Signature:	Andrew Gundlach
Name/Title:	Individual
Date:	02/13/2026

Exhibit Information

Exhibit 99.1 SUBSIDIARY INFORMATION

FAQ

How many Cellectar Biosciences (CLRB) shares does Bleichroeder report owning?

Bleichroeder-related entities report beneficial ownership of 200,000 Cellectar Biosciences common shares. This stake is held through Bleichroeder LP as investment adviser for various clients, which means the clients ultimately receive dividends and sale proceeds associated with these shares.

What percentage of Cellectar Biosciences (CLRB) does Bleichroeder beneficially own?

Bleichroeder is deemed to beneficially own 4.61% of Cellectar Biosciences’ common stock. This percentage reflects 200,000 common shares believed to be outstanding, held for advisory clients rather than for direct corporate control purposes.

Which entities and individuals are listed as reporting persons for CLRB in this Schedule 13G/A?

The Schedule 13G/A lists Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach as reporting persons. All three report the same 200,000-share position, with sole voting and dispositive power and no shared voting or dispositive authority disclosed.

Does Bleichroeder intend to influence control of Cellectar Biosciences (CLRB)?

The filing states the securities were acquired and are held in the ordinary course of business. It specifically certifies they were not acquired and are not held to change or influence control of Cellectar Biosciences, or in connection with any control-related transaction.

Who ultimately benefits from the CLRB shares managed by Bleichroeder LP?

Clients of Bleichroeder LP ultimately benefit from the Cellectar Biosciences shares. The filing explains these clients have the right to receive, and direct the receipt of, dividends and proceeds from the sale of the 200,000 common shares held in their accounts.

What type of filing did Cellectar Biosciences (CLRB) receive from Bleichroeder?

Cellectar Biosciences received an Amendment No. 1 to Schedule 13G. This updated ownership report reflects Bleichroeder’s 200,000-share, 4.61% beneficial stake in CLRB common shares and confirms the holdings are for ordinary-course investment advisory purposes.